Home › B-Cell Lymphoma › Pennsylvania
B-Cell Lymphoma clinical trials in Pennsylvania
16 studies for B-Cell Lymphoma are looking for participants at sites in Pennsylvania.
Cities in Pennsylvania
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Children's Hospital of Philadelphia, Philadelphia
RecruitingObservational study
Ages 0 to 38 · All sexes · Updated Oct 1, 2026 · NCT06131801A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
- Penn State Milton S Hershey Medical Center, Hershey
- McGlinn Cancer Institute, West Reading
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT06742996A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- University of Pennsylvania Abramson Cancer Center, Philadelphia
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07101328A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
- Children's Hospital of Philadelphia, Philadelphia
RecruitingPhase 1
Ages 0 to 18 · All sexes · Updated Sep 16, 2026 · NCT06173518Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
- Research Site, Philadelphia
- Research Site, Pittsburgh
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT06526793A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
- Fox Chase Cancer Center, Philadelphia
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT06634589A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
- Research Site, Philadelphia
- Research Site, Pittsburgh
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT06564038Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
- UPMC Hillman Cancer Center, Pittsburgh
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT07520006Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Lehigh Valley Topper Cancer Center Institute, Allentown
- Thomas Jefferson University, Philadelphia
- West Penn Hospital, Pittsburgh
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 25, 2026 · NCT05826535A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT04104776CD45BE-HSPC + CART-45 Cells
- University of Pennsylvania, Philadelphia
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 10, 2026 · NCT07451054A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Allegheny Health Network, Pittsburgh
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 4, 2026 · NCT07188558DALY II USA/ MB-CART2019.1 for DLBCL
- Allegheny Health Network Cancer Institute, Pittsburgh
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 13, 2026 · NCT04792489SynKIR-310 for Relapsed/Refractory B-NHL
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Apr 14, 2026 · NCT06544265Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
- AHN Cancer Institute - West Penn Hospital, Pittsburgh
RecruitingPhase 2
Ages 18 to 79 · All sexes · Updated Jan 13, 2025 · NCT05281809Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Children's Hospital of Philadelphia, Philadelphia
RecruitingPhase 1
Ages 1 to 21 · All sexes · Updated Dec 6, 2024 · NCT05476770From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.